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The high and sometimes most complex serologic cross-reactivity 
among the hantaviruses has complicated the investigations con- 
cerning potential human infections and diseases caused by the 
newly discovered viruses and has sometimes also made old sero- 
epidemiologic data uncertain. Recent analyses by neutralization assay 
and direct RT-PCR have proven Dobrava (DOB) virus as the agent 
of severe HFRS in Bosnia-Herzegovina, Greece, Albania, Slovenia 
and Germany Moreover, DOB has been shown to cause human 
infections also in north-eastern Europe, e.g. in Estonia and western 
Russia. These findings have major implications for the interpretation 
of serologic data and for future vaccine strategies. 
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Clinically important strains of hantaviruses of the Old World (OW- 
HTV) isolated so far are Hantaan (HTN, 1977), Seoul (SEO, 1982). 
Puumala (PUU, 1983). and Dobrava (DOB, 1988). PUU is the 
etiologic agent of nephropathia epidemica (NE), spread by red bank 
voles throughout Russia and northwest Europe. In contrast to New 
World HTV, which primarily affect the lung, OW-HTV induce 
variable degrees of (transient) proteinuria and acute renal failure 
(ARF); hence the W H O  denomination of hemorrhagic fever with 
renal syndrome (HFRS). However, internal hemorrhages are present 
in only 25% of HTN or DOB cases, and ARF can be absent or 
minimal. Exceptional complications in H T N  are hemorrhagic 
necrosis of the pituitary and/or adrenal glands, and can consist in 
PUU of acute pulmonary edema, pericarditis, acalculous chole- 
cystitis, encephalitis, and Guillain-BarrC syndrome. We noted acute 
myopia with blurred vision, conjunctival suffusion, chemosis, 
diplopia, uni- or bilateral acute glaucoma, retinal bleeding, and even 
transient blindness in up to 25% of PUU cases. 
Initial laboratory anomalies common to most HTV infections, and 
indicative of clinical severity, are (transient) thmnibocytopenia, and 
strikingly low serutn cholesterol, combined with high triglyceride 
levels. Since cytopathic effects are conspicuously lacking, 
imniunopathologic mechanisms, determined by host factors, and 
capillary leakage in target organs are presumably the key factors in 
pathogenesis. Treatment is supportive, but can include dialysis and/or 
ventilation. So far, the only current prophylaxis consists of reduced 
exposure to aerosolized rodent excreta. 
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Hantavirus infections are asymptomatic in their adult carrier rodents, 
but cause in humans hemorrhagic fever with renal syndrome (HFRS) 
and hantavirus pulmonary syndrome, both with significant mortality. 
/3? integrins mediate entry of pathogenic hantaviruses. In cell culture, 
hantaviruses do not cause cytopathic effects. The mechanisms of 
disease are not well understood. Cytotoxic T-cells have been demon- 
strated but their role is not clear. Increased capillary permeability is 
central in the pathogenesis of hantavirus infections. Inflammatory 
mediators of the host immune response presumably play a significant 
role in the capillary leak that may result in abrupt hypotension and 
shock. Mediators released by activated macrophages, including NO 
and TNF-alpha, are considered important. One of our aiins is to 
define the molecular determinants of hantavirus pathogenicity and to 
learn why the outcome of hantavirus-human interaction varies 
between individuals. It seems that both the genetic characteristics of 
the virus and the genetic susceptibility of patients contribute to this 
variability. In the carrier rodents, hantaviruses are composed of a 
genetic swarm of quasi-species. Adaptation from rodents to primate 
cells is selective and leads to defined genetic changes. 
There is suggestive evidence that natural reassortant hantaviruses 
are involved in human infection. We have linked the severity of 
Puumala hantavirus infection (nephropathia epidemica, NE) to 
certain host genes. HLA alleles B8 DR3 and DQ2 are strongly 
associated with severe NE and with hantavirus PCR positivity, HLA 
B27 is associated with mild NE, and the high-producer allele of 
TNF-alpha is a part of the susceptibility M H C  haplotype in severe 
NE . 
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Influenza viruses are prototypic re-emergent pathogens that represent 
continuing threats to human health. Influenza neuraminidase plays 
an essential role in replication by allowing release of virus from 
infected cells and facilitating spread within the respiratory tract. The 
active enzyme site is highly conserved across influenza A and B 
viruses. Zanamivir (GGI 67) and GS4071 are potent, selective 
influenza neuraininidase inhibitors in vitro but have different 
pharmacokinetic properties. Both topical zanamivir and oral 
GS4104, the ethyl 'ester prodrug of (34071, are active in experi- 
mental animal and human infections. Phase I11 studies have 
confirmed that twice-daily inhaled zanamivir treatment ameliorates 
symptoms and, in high-risk persons, reduces complications. A 4- 
week prophylaxis study found 67% protection against influenza illness 
in ambulatory adults. Phase I11 trials of oral GS4104 have found that 
twice-daily dosing is effective in treating acute influenza in adults and 
also reduces the risk of complications by about one-half. Once-daily 
dosing was 82% effective in preventing influenza illness. Studies of 
these drugs for prevention of influenza in nursing homes, and for 
treatment of influenza in high-risk patients and children, and of 
nebulized zanamivir for treating serious influenza in hospitalized 
patients, are in progress. Intranasal delivery of trivalent, cold-adapted, 
live-attenuated influenza vaccine is highly protective in young 
children. Protection was shown last season against the A/Sydney drift 
variant, for which the injected vaccine provided minimal protection, 
and also in working adults. In summary, neuraminidase inhibitors and 
the intranasal cold-adapted vaccine provide new means of confront- 
ing the continuing threat of influenza infections. 
